CDK8-novel therapeutic opportunities

Ingeborg Menzl; Agnieszka Witalisz-Siepracka; Veronika Sexl

doi:10.3390/ph12020092

CDK8-novel therapeutic opportunities

Ingeborg Menzl
, Agnieszka Witalisz-Siepracka
, Veronika Sexl^*

^*Corresponding author for this work

Research output: Journal article (peer-reviewed) › Review article

44 Citations (Scopus)

Abstract

Improvements in cancer therapy frequently stem from the development of new small-molecule inhibitors, paralleled by the identification of biomarkers that can predict the treatment response. Recent evidence supports the idea that cyclin-dependent kinase 8 (CDK8) may represent a potential drug target for breast and prostate cancer, although no CDK8 inhibitors have entered the clinics. As the available inhibitors have been recently reviewed, we focus on the biological functions of CDK8 and provide an overview of the complexity of CDK8-dependent signaling throughout evolution and CDK8-dependent effects that may open novel treatment avenues.

Original language	English
Article number	92
Journal	Pharmaceuticals
Volume	12
Issue number	2
DOIs	https://doi.org/10.3390/ph12020092
Publication status	Published - 19 Jun 2019
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cancer
CDK8
Mediator complex

ASJC Scopus subject areas

Molecular Medicine
Pharmaceutical Science

Access to Document

10.3390/ph12020092

Cite this

@article{f3f30b52943742c6875519800a6972ae,

title = "CDK8-novel therapeutic opportunities",

abstract = "Improvements in cancer therapy frequently stem from the development of new small-molecule inhibitors, paralleled by the identification of biomarkers that can predict the treatment response. Recent evidence supports the idea that cyclin-dependent kinase 8 (CDK8) may represent a potential drug target for breast and prostate cancer, although no CDK8 inhibitors have entered the clinics. As the available inhibitors have been recently reviewed, we focus on the biological functions of CDK8 and provide an overview of the complexity of CDK8-dependent signaling throughout evolution and CDK8-dependent effects that may open novel treatment avenues.",

keywords = "Cancer, CDK8, Mediator complex",

author = "Ingeborg Menzl and Agnieszka Witalisz-Siepracka and Veronika Sexl",

note = "Publisher Copyright: {\textcopyright} 2019 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2019",

month = jun,

day = "19",

doi = "10.3390/ph12020092",

language = "English",

volume = "12",

journal = "Pharmaceuticals",

issn = "1424-8247",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "2",

}

TY - JOUR

T1 - CDK8-novel therapeutic opportunities

AU - Menzl, Ingeborg

AU - Witalisz-Siepracka, Agnieszka

AU - Sexl, Veronika

PY - 2019/6/19

Y1 - 2019/6/19

N2 - Improvements in cancer therapy frequently stem from the development of new small-molecule inhibitors, paralleled by the identification of biomarkers that can predict the treatment response. Recent evidence supports the idea that cyclin-dependent kinase 8 (CDK8) may represent a potential drug target for breast and prostate cancer, although no CDK8 inhibitors have entered the clinics. As the available inhibitors have been recently reviewed, we focus on the biological functions of CDK8 and provide an overview of the complexity of CDK8-dependent signaling throughout evolution and CDK8-dependent effects that may open novel treatment avenues.

AB - Improvements in cancer therapy frequently stem from the development of new small-molecule inhibitors, paralleled by the identification of biomarkers that can predict the treatment response. Recent evidence supports the idea that cyclin-dependent kinase 8 (CDK8) may represent a potential drug target for breast and prostate cancer, although no CDK8 inhibitors have entered the clinics. As the available inhibitors have been recently reviewed, we focus on the biological functions of CDK8 and provide an overview of the complexity of CDK8-dependent signaling throughout evolution and CDK8-dependent effects that may open novel treatment avenues.

KW - Cancer

KW - CDK8

KW - Mediator complex

UR - https://www.scopus.com/pages/publications/85069735901

U2 - 10.3390/ph12020092

DO - 10.3390/ph12020092

M3 - Review article

C2 - 31248103

AN - SCOPUS:85069735901

SN - 1424-8247

VL - 12

JO - Pharmaceuticals

JF - Pharmaceuticals

IS - 2

M1 - 92

ER -

CDK8-novel therapeutic opportunities

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this